Celcuity CELC Soars On Strong Phase 3 Cancer Data

Celcuity Inc. surged as positive breast cancer therapy trial updates spurred optimism, and stocks have been trading up by 18.96 percent.

Live Update At 12:32:07 EDT: On Monday, May 04, 2026 Celcuity Inc. stock [NASDAQ: CELC] is trending up by 18.96%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CELC has been trading like a biotech name in the middle of a major rerating. Over the last several weeks, Celcuity stock climbed from a close near $117 on 2026/04/10 to about $149 on 2026/05/04. That’s a strong uptrend, with CELC regularly putting in higher lows and respecting prior breakout levels on the daily chart.

Intraday on 2026/05/04, CELC showed heavy action between $145 and $149, with multiple tests of the high‑$140s. Pullbacks toward $145 kept getting bought, which tells traders that dip buyers are active and momentum remains intact. The early flush down to roughly $136 at the open was quickly reclaimed, another sign of aggressive demand.

More Breaking News

• SMMT Plunges As Summit Therapeutics Stock Suffers 27% Selloff
• FATE Stock Rises As Fate Therapeutics Showcases FT839 CAR T Data​
• NBIS Stock Climbs As Nebius Lands TD SYNNEX AI Deal
• TWO Surges As UWM Tops CrossCountry Mortgage Buyout Deal

Fundamentally, Celcuity is still a classic clinical‑stage biotech profile. The latest quarterly report shows negative net income of about $51M and operating cash burn around $36M. CELC posts deeply negative returns on equity and assets, while carrying long‑term debt near $322M. At the same time, Celcuity reports roughly $166M in cash and more than $441M in cash and short‑term investments, plus a strong current ratio above 10. For traders, this mix says one thing: dilution and losses are real, but CELC has runway to reach key regulatory events, so the chart is likely to trade more on headlines than on earnings for now.

Why Traders Are Watching CELC Right Now

CELC is front and center for momentum traders because its main drug, gedatolisib, just cleared a huge hurdle. Celcuity reported that the Phase 3 VIKTORIA‑1 trial in PIK3CA‑mutant HR+/HER2‑ metastatic breast cancer met its primary endpoint. Gedatolisib plus fulvestrant, with or without palbociclib, showed statistically significant and clinically meaningful progression‑free survival gains over alpelisib plus fulvestrant, with a generally well‑tolerated safety profile. In biotech, that kind of clean late‑stage win often rewrites the valuation script.

For CELC, this is not a one‑off data bump. Celcuity had already delivered positive results in the PIK3CA wild‑type setting. Now, combining the mutant and wild‑type VIKTORIA‑1 data, the company is talking about broad second‑line use in HR+/HER2‑ advanced breast cancer. That’s a much wider patient pool than a narrow mutation‑only label, and traders are quick to price in that kind of commercial upside.

Celcuity plans to submit a supplemental NDA to the FDA and other regulators off these PIK3CA‑mutant data. On top of that, gedatolisib already has Priority Review for the PIK3CA wild‑type population, with a set PDUFA date on 2026/07/17. For CELC traders, that means a defined run of catalysts: sNDA filing headlines, regulatory acceptance, and finally the decision date.

The Street is taking notice too. Citizens just initiated coverage of Celcuity with an Outperform rating and a $150 price target, explicitly calling out gedatolisib as the core value driver. When a name like CELC combines late‑stage clinical wins, a Priority Review clock, and fresh bullish coverage, it often becomes a magnet for event‑driven and breakout traders hunting for range expansion and high‑volume moves.

Conclusion

CELC sits in the sweet spot many biotech traders look for: real late‑stage data, a clear regulatory path, and a chart that already shows strong, liquid momentum. Celcuity’s Phase 3 VIKTORIA‑1 success in PIK3CA‑mutant HR+/HER2‑ metastatic breast cancer, layered on top of earlier wild‑type results, positions gedatolisib for potentially broad second‑line adoption if regulators sign off. The planned supplemental NDA, coupled with the existing Priority Review and 2026/07/17 PDUFA date, turns the CELC timeline into a series of definable catalysts rather than vague hopes.

Financially, Celcuity is still burning cash and posting sizable losses, which is typical for a development‑stage oncology name. The balance sheet, however, shows a sizable cash pile and strong liquidity, giving CELC room to reach those regulatory milestones. Traders should remember that valuation measures like a high price‑to‑book multiple or negative cash‑flow ratios matter less in the short term than news flow and tape action. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.” That mindset lines up well with how many short‑term biotech traders approach names like CELC: track the price action, wait for confirmation, and react to concrete data and catalysts rather than wishful thinking.

As Tim Sykes likes to say, “Pattern and catalyst matter way more than your opinion.” CELC now has both: a bullish biotech chart and real Phase 3 and regulatory catalysts that can drive sharp moves. For active traders studying Celcuity day by day, the key is to respect the volatility, focus on risk management, and let the data — not the hype — dictate the trade. This analysis is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.